| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report[7] | 2019 | 37.78 | 2020 | 2024 |  |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing[8] | 2015 | 15.51 | 2016 | 2020 |  |
| The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation[9] | 2018 | 15.38 | 2019 | 2024 |  |
| Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice[10] | 2019 | 15.31 | 2021 | 2024 |  |
| Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference[11] | 2009 | 13.14 | 2011 | 2014 |  |
| Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I[12] | 2010 | 11.44 | 2011 | 2015 |  |
| A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation[13] | 2016 | 10.8 | 2018 | 2021 |  |
| Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients[14] | 2004 | 10.58 | 2005 | 2009 |  |
| The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation[15] | 2014 | 10.42 | 2015 | 2019 |  |
| Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[16] | 2007 | 9.78 | 2008 | 2012 |  |